BLRX - BioLine Rx Ltd

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.06
+0.01 (+0.95%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.05
Open1.06
Bid1.05 x 2000
Ask1.12 x 2000
Day's Range1.05 - 1.09
52 Week Range0.80 - 1.38
Volume264,704
Avg. Volume451,522
Market Cap111.752M
Beta0.11
PE Ratio (TTM)N/A
EPS (TTM)-0.27
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.25
Trade prices are not sourced from all markets
  • PR Newswire12 days ago

    BioLineRx Ltd. Hosts Investor Breakfast Meeting in NY

    TEL AVIV, Israel, Dec. 5, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today hosts its investor breakfast meeting at the Convene Conference Center near Grand Central in New York, NY. Philip Serlin, Chief Executive Officer of BioLineRx, stated, "This annual event gives us the opportunity to directly meet with our investors for updates on our progress:  steady advancements on our multiple clinical programs in stem cell mobilization, combination immunotherapies and acute myeloid leukemia (AML), as well as our new and novel immuno-oncology therapy.

  • PR Newswire13 days ago

    BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML

    BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today positive overall survival data from the long-term follow-up part of the Phase 2a trial of BL-8040 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML). The results demonstrate that the combination of BL-8040 with high-dose Ara-C (HiDAC) in this difficult-to-treat patient population significantly improved overall survival, compared with historical data of HiDAC monotherapy. The long-term survival results from the Phase 2a study derive from the expansion phase of the study, which included 16 patients (out of 42 total patients enrolled in the study).

  • ACCESSWIRE18 days ago

    Today’s Research Reports on Trending Tickers: BioLineRx Ltd. and Opko Health, Inc.

    NEW YORK, NY / ACCESSWIRE / November 29, 2017 / U.S. markets closed at record highs Tuesday as the U.S. moved one stepped closer to a tax reform after a recent Senate vote. The Dow Jones Industrial Average ...

  • PR Newswire26 days ago

    BioLineRx Reports Third Quarter 2017 Financial Results

    TEL AVIV, Israel , Nov. 21, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for ...

  • PR Newswire27 days ago

    BioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted for Presentation at ASCO 2018 Gastrointestinal Cancers Symposium

    BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that an abstract with partial results from the monotherapy portion of BL-8040's Phase 2a COMBAT study in pancreatic cancer was accepted for presentation at the ASCO 2018 Gastrointestinal Cancers Symposium, to take place January 18-20, 2018 in San Francisco, CA. The Phase 2a study, named the COMBAT study, is an open-label, multicenter, single-arm trial designed to evaluate the safety and efficacy of the combination of BL-8040 and KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by Merck & Co., Inc., (known as MSD outside the United States and Canada), in up to 30 subjects with metastatic pancreatic adenocarcinoma.

  • PR Newswirelast month

    BioLineRx Ltd. to Host Investor Breakfast Meeting December 5, 2017 in New York

    BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will host an investor breakfast meeting on Tuesday, December 5, 2017 at the Convene Conference Center near Grand Central in New York, NY.

  • PR Newswirelast month

    BioLineRx to Report Third Quarter 2017 Results on November 21, 2017

    BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its unaudited financial results for the quarter ended September 30, 2017 on Tuesday, November 21, 2017, before the U.S. markets open. The Company will host a conference call on Tuesday, November 21, 2017 at 10:00 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer, and David Malek, Chief Business Officer. The conference call will be available via webcast and can be accessed through the Investor Relations page of BioLineRx's website.

  • PR Newswire3 months ago

    BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in AML Under Immunotherapy Collaboration

    BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the initiation of a Phase 1b/2 trial for BL-8040 in combination with atezolizumab (TECENTRIQ®), an anti-PDL1 cancer immunotherapy from Genentech, a member of the Roche Group. The trial, known as the BATTLE study (NCT03154827), will focus on the maintenance treatment of patients with intermediate and high-risk acute myeloid leukemia (AML) who have achieved a complete response (CR) following induction and consolidation therapy.

  • PR Newswire3 months ago

    BioLineRx to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York

    BioLineRx Ltd. (BLRX)(BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that its Chief Executive Officer, Philip Serlin, and its Chief Business Officer, David Malek, will present a company update at the 19th Annual Rodman & Renshaw Global Investment Conference at the Lotte New York Palace Hotel in New York City. BioLineRx is a clinical-stage biopharmaceutical company focused on oncology and immunology.

  • BioLineRx Moves a Regulatory Submission for BL-8040 Trial
    Zacks4 months ago

    BioLineRx Moves a Regulatory Submission for BL-8040 Trial

    BioLineRx (BLRX) forwards a regulatory submission to begin a phase III study to evaluate BL-8040 in combination with G-CSF for treatment of multiple myeloma.

  • PR Newswire4 months ago

    BioLineRx Announces Regulatory Submission of Phase 3 Registrational Study for BL-8040 in Stem Cell Mobilization

    TEL AVIV, Israel, Aug 21, 2017 /PRNewswire/ --BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the filing of regulatory submissions required to commence a randomized, controlled Phase 3 registrational trial of BL-8040 for the mobilization of hematopoietic stem cells for autologous transplantation in patients with multiple myeloma. The trial, named GENESIS, is expected to commence by the end of 2017, following receipt of regulatory approvals.

  • ACCESSWIRE4 months ago

    Investor Network: Bioline RX Ltd Sponsored ADR to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2017 / Bioline RX Ltd Sponsored ADR (NASDAQ: BLRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on Tuesday, August 8, 2017 at 10:00 ...

  • PR Newswire4 months ago

    BioLineRx Reports Second Quarter 2017 Financial Results

    TEL AVIV, Israel , Aug. 8, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for ...

  • PR Newswire5 months ago

    BioLineRx to Report Second Quarter 2017 Results on August 8, 2017

    Management to hold conference call at 10:00 a.m. EDT TEL AVIV, Israel , August 2, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology ...

  • 4 Biotech Stocks to Watch This Quarter
    GuruFocus.com5 months ago

    4 Biotech Stocks to Watch This Quarter

    Biotech could easily continue to grow as long-term trends remain in place

  • ACCESSWIRE5 months ago

    3 Biotech Stocks to Watch in August

    CORAL GABLES, FL / ACCESSWIRE / August 1, 2017 / Biotechnology stocks have remained hot this year. Since the last pullback prior to the U.S. presidential election, shares of companies across the sector ...

  • PR Newswire5 months ago

    BioLineRx Announces Additional Investment From BVF Partners L.P.

    BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that BVF Partners L.P. (BVF), its largest shareholder, has entered into a definitive agreement to make an additional, direct investment of $9.6 million in BioLineRx, increasing its economic interest in the Company to 24.9%. Each unit consists of 1 ordinary share, 0.35 of a Series A warrant, and 0.35 of a Series B warrant. The Series A warrants have an exercise price of $2.00 per ordinary share and a 4-year term.

  • BioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session
    Zacks5 months ago

    BioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session

    BioLine Rx Ltd (BLRX) shares rise over 5% in the last trading session.

  • BioLineRx/Roche Scan BL-8040-Tecentriq for Pancreatic Cancer
    Zacks5 months ago

    BioLineRx/Roche Scan BL-8040-Tecentriq for Pancreatic Cancer

    BioLineRx Ltd. (BLRX) announced that its partner Genentech, has initiated a phase Ib/II study, evaluating BL-8040 in combination Tecentriq (atezolizumab) for treatment of patients with metastatic pancreatic ductal adenocarcinoma.

  • PR Newswire5 months ago

    BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration

    BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that Genentech, a member of the Roche Group, has commenced a Phase 1b/2 study for BL-8040 in combination with atezolizumab (TECENTRIQ®), Genentech's anti-PDL1 cancer immunotherapy agent, evaluating the combination in metastatic pancreatic ductal adenocarcinoma. Up to 40 patients are planned to be enrolled in this Phase 1b/2, multicenter, randomized, controlled, open-label study to evaluate the clinical response, safety and tolerability, as well as multiple pharmacodynamic parameters, of BL-8040 in combination with atezolizumab. Initially, patients will receive BL-8040 injections as priming monotherapy for five consecutive days, after which, from day 8, they will receive both BL-8040 and atezolizumab, and continue with multiple treatment cycles for up to two years or until disease progression, clinical deterioration or unacceptable toxicity.

  • Top 10 Penny Stocks To Buy in 2017
    Insider Monkey6 months ago

    Top 10 Penny Stocks To Buy in 2017

    What are the top 10 penny stocks to buy in 2017? Out of thousands of stocks that are trading at price levels below $1.00, it can be hard to identify winning picks, especially since it’s no secret that the companies behind penny stocks may be involved in scams or other shady endeavors that will cause […]

  • Accesswire6 months ago

    Corporate News Blog - Concordia Announces Review of Strategic Alternatives; Views Itself on the Auction Block to Repay its $3.5 billion Debt

    Research Desk Line-up: BioLine Rx Post Earnings Coverage LONDON, UK / ACCESSWIRE / June 23, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Concordia ...

  • PR Newswire7 months ago

    BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination With Atezolizumab for Solid Tumors

    BioLineRx Ltd. (NASDAQ: BLRX, TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that Genentech, a member of the Roche Group, has filed a total of three regulatory submissions required to commence Phase 1b trials for BL-8040 in combination with atezolizumab (Tecentriq®), Genentech's anti-PDL1 cancer immunotherapy, for the treatment of patients with solid tumors. The trials for pancreatic, gastric and non-small cell cancer are expected to commence during the second half of 2017, after receipt of regulatory approval.

  • Accesswire7 months ago

    Investor Network: Bioline RX Ltd Sponsored ADR to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 25, 2017 / Bioline RX Ltd Sponsored ADR (NASDAQ: BLRX ) will be discussing their earnings results in their Q1 Earnings Call to be held May 25, 2017 at 10:00 AM Eastern Time. ...

  • PR Newswire7 months ago

    BioLineRx Reports First Quarter 2017 Financial Results

    TEL AVIV, Israel, May 25, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for ...